Meet the Japanese ‘doctor' who fixes toys for the elderly
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Wearable Devices Collaborates with Leading Japanese E-Commerce Platform to Expand Mudra Wearable Devices in Tech-Savvy Market
Mudra wearable devices use neural sensors to enable touchless control of digital devices across Apple, Android and Windows platforms. Yokneam Illit, Israel, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) (the 'Company' or 'Wearable Devices'), a technology growth company specializing in artificial intelligence ('AI')-powered touchless sensing wearables, recently announced a collaboration with Media Exceed Co., Ltd. ('Media Exceed'), a leading e-commerce company in Japan. Under this agreement, Media Exceed will serve as a non-exclusive reseller of the award-winning Mudra Band and Mudra Link, bringing Wearable Devices' innovative neural technology to Japan, one of the world's most tech-savvy consumer bases. This collaboration aims to enhance the availability of Wearable Devices' neural interface products in Japan, leveraging Media Exceed's robust e-commerce platform and market expertise. The collaboration supports both drop shipping and wholesale models, ensuring streamlined order fulfillment and localized customer support for Japanese buyers. See the Mudra Band and Mudra Link in action at 'This collaboration is a major step in our mission to revolutionize how people interact with technology,' said Asher Dahan, Chief Executive Officer of Wearable Devices. 'Japan's appetite for innovation makes it the perfect market to showcase our Mudra products, and we're thrilled to collaborate with Media Exceed to accelerate our global growth.' Shinya Kasuga, Chief Executive Officer of Media Exceed, said: 'We are eager to start working with Wearable Devices and bring the innovative Mudra products to the Japanese market. Their neural interface technology aligns perfectly with our vision to introduce cutting-edge solutions that enhance the way people interact with digital devices.' The Mudra Band, designed for Apple Watch users, and the Mudra Link, compatible with Android and Windows devices, utilize proprietary Surface Nerve Conductance sensors to detect neural signals from subtle finger movements. These signals are translated into intuitive commands, enabling touchless control of digital devices. The Mudra Link was recently showcased at CES® 2025, where it received an Innovation Award in the XR Technologies and Accessories category. Media Exceed will offer these products through its online platforms, providing Japanese consumers with direct access to Wearable Devices' innovative technology. The collaboration is expected to enhance user experience and satisfaction by combining advanced wearable technology with Media Exceed's customer-centric approach. About Wearable Devices Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) is a growth company pioneering human-computer interaction through its AI-powered neural input touchless technology. Leveraging proprietary sensors, software, and advanced AI algorithms, the Company's consumer products - the Mudra Band and Mudra Link - are defining the neural input category both for wrist-worn devices and for brain-computer interfaces. These products enable touch-free, intuitive control of digital devices using gestures across multiple operating systems. Operating through a dual-channel model of direct-to-consumer sales and enterprise licensing and collaborations, Wearable Devices empowers consumers with stylish, functional wearables for enhanced experiences in gaming, productivity, and extended reality (XR). In the business sector, the Company provides enterprise partners with advanced input solutions for immersive and interactive environments, from augmented reality/virtual reality/XR to smart environments. By setting the standard for neural input in the XR ecosystem, Wearable Devices is shaping the future of seamless, natural user experiences across some of the world's fastest-growing tech markets. Wearable Devices' ordinary shares and warrants trade on the Nasdaq Capital Market under the symbols 'WLDS' and 'WLDSW,' respectively. Forward-Looking Statements Disclaimer This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the 'safe harbor' created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as 'believe,' 'expect,' 'may,' 'should,' 'could,' 'seek,' 'intend,' 'plan,' 'goal,' 'estimate,' 'anticipate' or other comparable terms. For example, we are using forward-looking statements when we discuss the aim of our collaboration with Media Exceed, benefits and advantages of our products and technology, that this collaboration is a major step in our mission to revolutionize how people interact with technology, that collaboration with Media Exceed will accelerate our global growth and that the collaboration is expected to enhance user experience and satisfaction. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the trading of our ordinary shares or warrants and the development of a liquid trading market; our ability to successfully market our products and services; the acceptance of our products and services by customers; our continued ability to pay operating costs and ability to meet demand for our products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; our ability to comply with applicable regulations; and the other risks and uncertainties described in our annual report on Form 20-F for the year ended December 31, 2024, filed on March 20, 2025 and our other filings with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Investor Relations Contact Michal Efraty IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
5 hours ago
- Medscape
Oximetry Weak for Predicting OSA in Kids With Down Syndrome
TOPLINE: Nocturnal pulse oximetry (NPO) indices, such as the 3% and 4% Oxygen Desaturation Indices (ODI3 and ODI4, respectively), demonstrated moderate sensitivity and specificity for detecting moderate and severe obstructive sleep apnoea (OSA) in children with Down syndrome but showed low sensitivity for detecting mild OSA. METHODOLOGY: Researchers conducted a retrospective study to evaluate the ability of two NPO indices (ODI3 and ODI4) for predicting OSA in children with Down syndrome. They compared cardiorespiratory polygraphy (CRP) and NPO recordings in 387 children aged 2-16 years with Down syndrome (median age, 6.1 years; 46.7% girls) who were referred for the evaluation of OSA at two tertiary sleep centres in the UK between May 2016 and May 2024. OSA was defined as having an Obstructive Apnoea-Hypopnoea Index (OAHI) of one or more events per hour and classified according to severity as mild (one or more to less than five events per hour), moderate (five or more to less than 10 events per hour), or severe (10 or more events per hour). Two-by-two tables were used to determine the sensitivity and specificity of various cutoff values of NPO parameters for predicting OSA: oxygen saturation (SpO2), ODI3, ODI4, minimum SpO2, the Delta 12-second index, and the percentage of analysis time with SpO2 < 94%, < 92%, and < 90%. TAKEAWAY: Of 387 children, 265 (68.5%) had OSA, with 164 (42.4%) having mild OSA, 51 (13.2%) having moderate OSA, and 50 (12.9%) having severe OSA. An ODI3 threshold of 19 or more events per hour provided the highest combined sensitivity and specificity for predicting OSA (59.2% and 74.6%, respectively); increasing the threshold to 23 or more events per hour provided the highest combined sensitivity and specificity for an OAHI of five or more events per hour (70.3% and 79.7%, respectively) and 10 or more events per hour (82.0% and 73.9%, respectively). An ODI4 threshold of 10 or more events per hour yielded moderate sensitivity (76.2%) and specificity (75.2%) for predicting OSA; a threshold of 13 or more events per hour provided moderate sensitivity (72.0%) and high specificity (80.7%) for an OAHI of 10 or more events per hour. For predicting an OAHI of one or more events per hour, an ODI3 threshold of 19 or more events per hour yielded a positive predictive value of 83.5% and a negative predictive value of 45.7%, and an ODI4 of eight or more events per hour yielded a positive predictive value of 82.8% and a negative predictive value of 47.5%. IN PRACTICE: "Oximetry alone does not provide a reliable diagnostic tool for evaluating OSA in children with DS [Down syndrome]; therefore, we recommend CRP/PSG [polysomnography] should be performed," the authors wrote. SOURCE: This study was led by Hannah Vennard, Paediatric Respiratory and Sleep Medicine, Royal Hospital for Children, Glasgow in Glasgow, Scotland. It was published online on August 11, 2025, in Archives of Disease in Childhood. LIMITATIONS: Using CRP instead of polysomnography meant that total sleep time was estimated, which could have potentially led to the underestimation of the OAHI due to underscoring of hypopnoeas not associated with desaturation when arousals from sleep could not be detected. The total recording time of stand-alone oximetry does not match the total sleep time measured using CRP, which may have affected the accuracy of oximetry indices in predicting the OAHI. The high prevalence of central apnoeic events may have affected the accuracy of ODI thresholds for predicting OSA. DISCLOSURES: This study did not receive any funding from any source. The authors declared no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication
Medscape
5 hours ago
- Medscape
Biologic Dose Adjustments May Benefit Patients With IBD
TOPLINE: The dose escalation of biologic therapy was effective in achieving remission in up to approximately half of patients with inflammatory bowel disease (IBD), with a probability of sustaining the escalated dose ranging from 71% to 88% at 24 months across different biologics. Dose de-escalation was proved to be feasible in selected patients, with 89%-100% maintaining clinical remission at 12 months. METHODOLOGY: In this cross-sectional study, researchers analysed patients with IBD enrolled in a Spanish registry (January 2012 to December 2022) from 72 Spanish centres to assess the frequency, persistence, and effectiveness of the dose escalation of biologics or their discontinuation. Adult patients with a diagnosis of Crohn's disease or ulcerative colitis (UC) who received standard maintenance doses of infliximab (5 mg/kg every 8 weeks), adalimumab (40 mg every other week), golimumab (50 and 100 mg monthly for those with weight ≤ 80 kg and > 80 kg, respectively), vedolizumab (300 mg every 8 weeks), or ustekinumab (90 mg every 8 or 12 weeks) were identified. Overall, 5096 patients underwent dose escalation, defined as any increase in the dose and/or shortening of the dosing interval from the standard schedule's doses. Conversely, dose de-escalation was defined as the reduction in the dose and/or lengthening of the dosing interval following an escalation regimen, occurring in 669 patients. The effectiveness of dose escalation or de-escalation was assessed on the basis of clinical remission with or without corticosteroids, response, and non-response. Factors associated with drug discontinuation after dose escalation were also assessed, with a median follow-up duration ranging from 9 to 24 months across different biologics. TAKEAWAY: Among patients on various biologics, the incidence rate of dose escalation per patient-year of follow-up was 5% for those on infliximab, 7% for those on adalimumab, 7% for those on golimumab, 10% for those on vedolizumab, and 12% for those on ustekinumab. Remission was achieved in 32%-49% of patients after dose escalation, with a probability of maintaining the escalated dose ranging from 71% to 88% at 24 months across different biologics. Incidence rates of dose de-escalation per patient-year of follow-up ranged from 3% to 9% across various biologics. Factors associated with drug discontinuation after dose escalation were previous biologic exposure and the duration of IBD (for infliximab), monotherapy (for adalimumab), and the presence of UC (for ustekinumab). Clinical remission was observed in 89%-100% of patients who underwent dose de-escalation, with a probability of maintaining the de-escalated dose ranging from 82% to 90% at 12 months across different biologics. Factors linked to relapses after dose de-escalation were previous biologic exposure (for infliximab) and age at dose de-escalation (for adalimumab). IN PRACTICE: "While dose escalation offers a clear benefit in cases of LOR [loss of response], with a high proportion of patients achieving response (and remission) over time, dose de-escalation seems feasible for long-term management in selected patients, although it must be approached with caution," the authors of the study wrote. SOURCE: This study was led by Cristina Rubín de Célix, MD, PhD, Department of Gastroenterology, Hospital Universitario de Fuenlabrada, Madrid, Spain. It was published online on August 08, 2025, in Alimentary Pharmacology and Therapeutics. LIMITATIONS: Drug trough levels and antidrug antibodies were not routinely measured prior to dose escalation and de-escalation. The small number of patients undergoing vedolizumab or ustekinumab dose de-escalation precluded definitive conclusions about these regimens. Response after dose escalation and outcomes following dose de-escalation were determined solely by clinician judgement as endoscopic confirmation was unavailable. DISCLOSURES: This study received support from Eli Lilly and Company for the statistical analysis, medical writing, and publication fees alone. Several authors reported receiving education funding, support for congress and conference attendance or travelling, speaker fees, research support, and consulting fees and serving as speakers, consultants, and advisory members for various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
